Print Friendly Page

Protocol No. S1612

Principal Investigator Mattison, Ryan

Phase II/III

Age Group Adult

Scope National

Sponsor Type National

Title A Randomized Phase II/III Trial of "Novel Therapeutics: Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older

Applicable Disease Sites Hematologic cancers, other; Leukemia

Drugs Involved 5-AC (azacitidine); 5-AZA (azacitidine); 5-azacitidine (azacitidine); BMS-936558 (Nivolumab); Dacogen (decitabine); Nivolumab; Opdivo (Nivolumab); PKC412 (midostaurin); ara-c (cytarabine); azacitidine; cytarabine; cytosar (cytarabine); cytosine arabinoside (cytarabine); decitabine; midostaurin

Status Open (affiliates only)

Participating Institutions Aspirus UW Cancer Center (formerly Riverview Hospital); Aspirus Wausau Hospital, Aspirus Regional Cancer Center; Langlade Memorial Hospital, Aspirus Regional Cancer Ctr